In the prospective analysis phase, patients undergo routine Multiphasic Contrast-Enhanced Computed Tomography (CE-CT) imaging. The scans are evaluated through two parallel pathways: standard radiologist interpretation (without AI input) and independent AI analysis. When diagnostic discrepancies occur, a senior radiologist or multidisciplinary expert panel reviews the case and provides the definitive diagnosis.

The system automatically processes all eligible same-day scans and generates results for review the following day. To maintain efficient AI-human collaboration while preserving the standard clinical workflow, the conventional radiological interpretation process remains unchanged (first-line radiologists provide initial reports followed by senior radiologists' review). A dedicated senior radiologist then evaluates any discordances between AI findings and primary radiological report. For complex cases, the review process escalates to a consensus review panel (i.e., pre-designated senior radiologists, Multidisciplinary Team (MDT)). The MDT can recommend clinical interventions including follow-up (e.g., additional imaging examinations, active surveillance), surgical procedures, or adjustments to adjuvant therapy (initiation or modification of treatment regimens). All discordant cases and their outcomes are systematically documented for longitudinal tracking and follow-up analysis.

AI-human collaboration for CE-CTs diagnosis

Hypnosis Intervention

Participants receive hypnosis sessions designed to improve attention and reduce fatigue.

Hypnosis sessions designed to improve attentional control and reduce fatigue in patients with neurological conditions (stroke, TBI, MS). The intervention involves guided hypnotic induction and suggestions tailored to enhance cognitive focus and energy management.

Hypnosis

Sham Hypnosis Control

Participants receive sham hypnosis sessions serving as a control condition.

Beatrice Ottiger, MSc OT

Participants found to be eligible to take part in this study, you will receive nivolumab and relatlimab by vein over about 30 minutes on Day 1 of every 28-day study cycle (about every 4 weeks).

Diagnostic Laboratory Biomarker Analysis

Nivolumab

Relatlimab

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

LX102 subretinal injection

Administer human matrix cells by intravenous infusion or nasal drip once every two weeks, for a total of 5 administrations.

The human-derived stromal cells were administered intravenously once every two weeks, for a total of 5 times. Among them, half of the subjects (10 people) received intranasal administration of human-derived stromal cells once a day, in the morning and evening, from the 6th to the 8th day after each administration; the remaining subjects (10 people) received nasal administration of placebo once a day, in the morning and evening, from the 6th to the 8th day after each administration.

Human-derived stromal cells

Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

Inosine

Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Patients with advanced radioactive-iodine refractory DTC who progressed to previous TKIs (including but not limited to lenvatinib or sunitinib). Patients will have not received previously cabozantinib, selective small-molecule BRAF kinase inhibitors, immune checkpoint inhibitor therapy, or systemic chemotherapy regimens.

* All enrolled patients will receive cabozantinib at a fixed dose of 60 mg once a day (QD). Patients will continue study treatment until PD (either clinical or radiological), or until unacceptable toxicity, the need for another systemic anticancer treatment, or other reasons for treatment discontinuation.
* Patients will take the tablet(s) once daily at bed time except for Week 1 Day 1: the first dose of study treatment will be administered in the clinic so that each patient can be observed for initial tolerability. Subsequent doses will be self-administered at home. The tablets should be swallowed whole and not crushed and administered fasting for at least 2 hours before through 1 hour after. If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose.

Cabozantinib

Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.

Hypnosedation

Questionnaire Administration

Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.

Verbal Support

Patients will be subjected to CESM; the two orthogonal mammographic projections, after intravenous administration of iodized contrast-enhancement (Omnipaque), will be performed.

Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the experimental procedure.

With visible contrast-enhancement, stereotactic biopsy will be performed under CESM guidance. After administration of an additional dose of iodized contrast-enhancement (Omnipaque), the insertion of the biopsy needle and the biopsy sampling will be targeted on the area of greatest enhancement in the context of calcifications. In the absence of contrast-enhancement, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area. At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).

Contrast enhanced mammography guided biopsy (diagnostic procedure)

Patients will be subjected to stereotactic biopsy Mammotome as normal clinical practice.

Surgical and medical treatments will be defined accordingly to the imaging and histological findings obtained with the standard procedure.

For all lesions, stereotactic biopsy Mammotome will be performed, using X-ray guidance. The insertion of the biopsy needle and biopsy will be targeted on the most suspicious calcification cluster or area.

At the end of the procedure, a metal clip marker will be placed in the biopsy site; the placement will be verified with dual orthogonal mammography projection (as regular clinical practice).

Mammography guided biopsy (diagnostic procedure)

Women with positive mammography for calcifications without mass, requiring biopsy

N=15 patients from 2025, in which management and treatment of arrhythmias and or myocardial dysfunction were driven by the panel

Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis

The 15 patients managed and treated for arrhythmias or myocardial dysfunction in 2024 without applying the myocarditis panel

Azienda Ospedaliero, Universitaria Ospedali Riuniti

Francesco Bianco, M.D., Ph.D., MSc., FEACVI

Federica Zallocco, M.D.

Bianca Lattanzi, M.D., Ph.D.

Alessia Omenetti, M.D., Ph.D.

Francesca C. Surace, M.D.

Emanuela Berton, M.D.

Alessandra Palpacelli, M.D.

Valentina Bucciarelli, M.D., Ph.D.

Denosumab is a sterile, preservative-free, clear, colorless to pale yellow solution. Each 1 mL single-dose prefilled syringe of denosumab contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2.

Denosumab

Normal Saline 1.0 ml subcutaneous injection

Placebo is 1 mL of normal saline drawn up in a commercially available syringe.

Placebo

Tiffany Grimes

Julia Smith

Anath Shalev, MD

Fouad Kandeel, MD, PhD

Hannah Lease

Carmella Evans-Molina, MD

120mg of denosumab，d1 in a 28-days cycle；200mg of anti-PD-1 inhibitor, d1 in a 21-days cycle；500mg/m2 of pemetrexed, d1 in a 21-days cycle; AUC4-5 of carboplatin, d1 in a 21-days cycle, for 4-6 cycle

denosumab combined anti-PD-1 inhibitor with chemotherapy

Zhang chief physician

Women with uterine fibroids randomized to treatment group

The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D

Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol

Women with uterine fibroids randomized to placebo group

Massimo Stomati, Ph.D

Andrea Tinelli, Ph. D

Patients will receive at least 12 months of maintenance elranatamab therapy. Patients will have MRD testing within clonoSEQ every 6 months. If 2 consecutive tests are negative, elranatamab will be stopped and the patient will go on observation schedule.

Once a patient starts the observation schedule, standard disease monitoring will be performed every 3 months and bone marrow-based MRD will be performed every 6 months until MRD recurrence, disease progression or end of study period (patients' on-study status will be a maximum of 36 months for treatment and intensive observation combined). Patients who experience MRD recurrence will be re-treated per study protocol. A patient may move back to the observation schedule after treatment re-initiation provided the same criteria as above are met (2 consecutive negative MRD tests). Patients who are determined to have progressive disease per IMWG criteria (whether on treatment or observation schedule) will transition off study.

\- Elranatamab will be dosed in 28-day cycles as follows:

* C1D1: 12 mg SC priming dose
* C1D4: 32 mg SC priming dose
* C1D8, C1D15, C1D22: 76 mg SC
* Cycle 2 and all subsequent cycles: 76 mg SC on D1 and D15

Elrantamab

clonoSEQ

Michael Slade, M.D.

John F DiPersio, M.D., Ph.D.

Ravi Vij, M.D.

Li Ding, Ph.D.

Feng Gao, M.D., Ph.D.

lactobacillus rhamnosus once daily for 12 weeks

Lactobacillus rhamnosus

Patients with bladder tumors will undergo BLC TURBT

Blue light cystoscopy uses hexyl aminolevulinate (HAL, branded in the United States as Cysview), a prodrug which accumulates in the bladder tumors and improves the tumor's visualization.

Cysview

Karl Storz D-Light C Photodynamic Diagnostic (PDD) system

Patients with bladder tumors will undergo WLC TURBT

Rana Harb

Faizah Karim

Arm 1 is those participants randomized to use of CGM in a continuous fashion; CGM use for the duration of 9 months.

Continuous Glucose Monitoring (CGM) is a technology used to measure glucose levels in people with diabetes. Unlike traditional finger prick self-monitoring of blood glucose (SMBG), CGM devices provide continuous and real-time glucose readings throughout the day and night.

CGM systems consist of a small sensor that is inserted under the skin to measure glucose levels in the interstitial fluid, a transmitter that sends the glucose data to a receiver or smartphone, which shows the glucose readings. The sensor measures glucose levels automatically at regular intervals, eliminating the need for frequent finger pricks.

CGM devices can track glucose trends, identify high or low glucose levels, and provide alerts for hypo- or hyperglycemia. This can help individuals make more informed decisions regarding their diabetes management, such as adjusting insulin doses, dietary choices, or physical activity levels.

Continuous glucose monitor

Arm 2 is those participants randomized to intermittent use of CGM; CGM use for 4 time points consisting of 2 weeks of CGM use each, for the duration of 9 months.

Arm 3 is those participants randomized to standard of care; regular use of self-monitoring of blood glucose (SMBG) for the duration of 9 months.

Foundation for Innovative New Diagnostics, Switzerland

It will have six 30-minute sessions delivered by a clinical psychologist in Hong Kong Children's Hospital or home depend on participants' preference on six consecutive Saturdays in a standard sequence: (1) psychoeducation which provides information on sleep, its function and characteristics, (2) sleep hygiene, in which guidelines that promote healthy sleep are followed, (3) stimulus control, which breaks the association between bedtime and anxiety by avoiding any activities in bed not related to sleep; (4) sleep restriction, which limits the amount of time in bed to increase the sleep drive, and (5) cognitive restructuring, which replaces negative thoughts of sleep with constructive thoughts; and (6) relaxation techniques that can quiet the mind and the body in preparation for sleep. A sleep diary will be provided along with handouts and worksheets for skill acquisition and practice.

CBT-I

The same length and delivery mode as VR hypnosis, but without a hypnosis component. The VR relaxation group will allow us to distinguish the effects of VR from those of VR hypnosis.

Participants will take part in a VR relaxation intervention supervised by a research assistant in Hong Kong Children's Hospital or participants' home depend on participants' preference, which comprises six 30-minute sessions, will be conducted on 6 consecutive Saturdays. The head-mounted display will show five relaxing scenarios (exploring an island, walking through a forest, observing different animals, climbing a mountain, and swimming in the sea), but without a hypnosis component.

VR relaxation

Participants will individually complete VR hypnosis, comprising six 30-minute sessions, conducted by a clinical psychologist on 6 consecutive Saturdays in Hong Kong Children's Hospital or home depend on participants' preference. Participants will be asked to wear head-mounted glasses which can display different scenarios. The participant will select one scenario on the basis of preference. In phase 1 (induction), a narrator will ask the participant to complete various tasks, such as naming animals that participants see. In phase 2 (deepening), the glasses will continue to show the relaxing scenery, with the narrator guiding the participant to pay attention to their breathing and muscle movements. In phase 3 (suggestion), participants will be guided to change negative thoughts and behaviors arising in response to poor sleep. In phase 4 (reawakening), the participants will be guided to return to the peaceful scene with a renewed sense of focus, such that participants will sleep well.

VR hypnosis

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the clinically healthy group.

In this study, 15 periodontitis patients with RA, 15 healthy individuals with RA, 15 systemic healthy periodontitis patients and 15 systemic periodontally healthy individuals will be included. ANGPTL-4 biomarker and other biomarkers (MMP-13, TNF-α, IL-6) that have not been previously analysed in the serum and saliva of both RA and periodontitis patients will be evaluated before and 3 months after COPT. Clinical parameters (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing), biochemical evaluations of serum, saliva and gingival samples will be performed and correlated with clinical parameters at baseline and 3 months after COPT in all individuals with periodontitis included in the study.

ELISA (Enzyme-Linked ImmunoSorbent Assay)

Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. ANGPTL-4 analysis will be performed by ELISA in saliva and serum of individuals. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.

Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and serum will be repeated 12 weeks after the treatment. ANGPTL-4 analysis will be performed by ELISA in saliva and serum of individuals. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontitis with rheumatoid arthritis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.

Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) salivary sample and serum fluid will be taken from all individuals at the beginning of the study. ANGPTL-4 levels will be examined to evaluate before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample and serum will be collected from the healthy individuals with RA group.

Patients assigned to the Usual Care arm will receive current usual care and will not receive direct patient outreach or any visit-based interventions from this trial.

Patient will not receive direct outreach prompting them to schedule and/or complete colorectal cancer screening.

No Direct Patient Outreach

Patient's clinician will not receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will not receive a text message 3 days after visit reminding them to complete colorectal cancer screening.

No Nudge/Text

Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm will not receive visit-based interventions.

Patient will receive direct outreach including an order to schedule and complete colonoscopy.

Direct Patient Outreach: Colonoscopy Only

Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.

Patient's clinician will receive an alert prompting them to discuss colorectal cancer screening with their patient upon visit. Patient will also receive a text message 3 days after visit reminding them to complete colorectal cancer screening.

Visit-Based Nudge/Text

Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm will not receive visit-based interventions.

Patient will receive direct outreach including an order to schedule and complete colonoscopy then an at-home fecal immunochemical test (FIT) if colonoscopy is not completed.

Direct Patient Outreach: Sequential Choice

Using bulk ordering, patients assigned to this arm will receive an order for colonoscopy and direct outreach (via text message and either the electronic patient portal or mailed letter, depending on their patient portal status) informing them they are overdue for CRC screening. If not completed, patients will receive an order and a mailed fecal immunochemical test (FIT) with a reminder to complete CRC screening. Patients randomized to this arm who attend a visit with their Primary Care Physician (PCP) will additionally receive a visit-based, clinician directed nudge to discuss colorectal cancer screening and a follow-up text 3 days post-visit to encourage screening completion.

CE-CT 진단을 위한 AI-인간 협업

최면

진단 실험실 바이오마커 분석, 니볼루맙, 렐라틀리맙

LX102 망막하 주사

인간 유래 기질 세포

이노신, 탁산/안트라사이클린/에리불린 메실레이트/비노렐빈/카페시타빈/카보플라틴/UTD1/플래티넘

카보잔티닙

최면, 설문지 관리, 언어적 지원

조영제 증강 유방 조영술 유도 생검(진단 절차), 유방 조영술 유도 생검(진단 절차)

심근염 진단을 받은 소아에서 바이러스 게놈, 세균 혈청학 및 염증 표지자 결정

데노수맙, 위약

데노수맙 항PD-1 억제제와 화학요법을 병용한

에피갈로카테킨 갈레이트, 비타민 D, 비타민 B6, D-카이로이노시톨, 위약

엘란타맙, 클로노SEQ

락토바실러스 람노수스, 위약

Cysview, Karl Storz D-Light C 광역학 진단(PDD) 시스템

연속 포도당 모니터

VR 최면, VR 이완 요법, 인지행동치료(CBT-I)

ELISA(효소결합면역흡착검사)

직접 환자 연락 없음, 직접 환자 연락: 대장내시경만, 직접 환자 연락: 순차적 선택, 방문 기반 넛지/문자, 넛지/문자 없음